ProQR Therapeutics NV expected to post a loss of 19  cents a share - Earnings Preview

ProQR Therapeutics NV

21/02/2022 19:34

* ProQR Therapeutics NV  PRQR.OQ   PRQR.O  is expected
to show a
rise in quarterly revenue when it reports  results on February
23 (estimated). 
    * The Leiden Zuid-holland-based  company is expected to
report  a
49.3% increase in revenue to €394.2 thousand from €264 thousand
a year ago, according to the mean estimate from 4 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for ProQR Therapeutics
NV is
for a loss of 19 cents per share. For the same quarter last
year, the company reported a loss of 26 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for ProQR
Therapeutics NV is $7.5​, about 83.7% above​ its last closing
price of $1.22. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in euros). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.20       -0.21      -0.22     Missed  -7.3
 Jun. 30 2021  -0.22       -0.22      -0.24     Missed  -7.8
 Mar. 31 2021  -0.25       -0.25      -0.25     Met     -0.1​
 Dec. 31 2020  -0.25       -0.25      -0.26     Missed  -3.6
 ​​Sep.        -0.30       -0.30      -0.26     Beat    13.5
 30 2020                                                
 Jun. 30 2020  -0.29       -0.33      -0.08     Beat    75.6​
 Mar. 31 2020  -0.34       -0.34      -0.32     Beat    6.4
 Dec. 31 2019  -0.35       -0.35      -0.39     Missed  -10.6
 This summary was machine generated February 21 at 19:33 GMT. 
All figures in euros  unless otherwise stated